IKIgor B. Khlynov

Igor B. Khlynov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Igor B. Khlynov has a total of 290 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gastroesophageal Reflux Disease and Barrett's Esophagus: Optimization of Patient Management and Cancer Prevention Measures (Literature Review and Resolution of the Expert Council of the Russian Gastroenterolog

    by V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, T. L. Lapina, D. N. Andreev, O. P. Alexeeva, S. A. Alekseenko, A. Yu. Baranovsky, O. V. Zayratyants, O. Yu. Zolnikova, et al.

    Aim: to summarize current clinical guidelines and meta-analyses data, and to present the main statements of the Expert Council of the Russian Gastroenterological Association regarding the optimization of endoscopic diagnosis, morphological verification, pharmacotherapy, and management strategies for patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Key points. In the Russian Federation, GERD is a highly prevalent disease: according to a meta-analysis involving over 30,000 individuals, the frequency of heartburn and/or regurgitation occurring once a week or more is 25 %. Proton pump inhibitors (PPIs) represent the cornerstone drug class for the treatment of GERD. Rebamipide targets altered epithelial permeability and mucosal inflammation. Combination therapy with PPIs and rebamipide improves symptoms in patients with non-erosive reflux disease, leading to positive morphological changes in the esophageal mucosa and improved control of nocturnal esophageal acid exposure. Ursodeoxycholic acid (UDCA) may be added to GERD therapy in the presence of biliary reflux or reflux gastritis. The clinical significance of GERD is determined not only by its high prevalence, chronic relapsing course, and impaired quality of life, but also by its precancerous potential. In individuals with GERD, the prevalence of Barrett’s esophagus is approximately 7 %, while the incidence of adenocarcinoma and/or high-grade dysplasia in the presence of low-grade dysplasia is 1.73% annually. Risk factors for the development of Barrett’s esophagus include male sex, age over 50 years, frequent GERD symptoms, tobacco smoking, obesity, and a positive family history. The management of patients with Barrett’s esophagus requires strict adherence to endoscopic and histological diagnostic protocols. Long-term PPI pharmacotherapy remains the standard of chemoprevention against neoplastic progression, demonstrating superiority over surgical treatment. Timely screening of high-risk individuals and adherence to endoscopic surveillance intervals enable the detection of dysplasia and esophageal adenocarcinoma at early, treatable stages. Conclusion. The Expert Council members proposed algorithms for the treatment of acute GERD exacerbation and maintenance therapy, as well as for the diagnosis and surveillance of patients with Barrett’s esophagus, taking into account current evidence and principles of evidence-based medicine. The literature review and the proposed algorithms aim to provide informational support for general practitioners, internists, gastroenterologists, and endoscopists in order to improve the quality of healthcare delivery and ensure effective prevention of esophageal adenocarcinoma.

  • Open Access

    Effectiveness and Safety of First-Line Empirical Eradication Therapy with Rebamipide: Results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

    by Dmitry S. Bordin, Dmitrii N. Andreev, Sayar R. Abdulkhakov, Irina N. Voynovan, Igor G. Bakulin, Natalia V. Bakulina, Ludmila G. Vologzhanina, Boris D. Starostin, Aiman S. Sarsenbayeva, Tatyana A. Ilchishina, et al.

    Background/Objective: Eradication of Helicobacter pylori typically uses acid-suppressing agents plus antimicrobials, but treatment failure may reach 20–30%. Adjunctive rebamipide has been proposed as a strategy to improve treatment outcomes. This study aimed to assess the effectiveness and safety of first-line empirical therapy when rebamipide was added to eradication regimens. Methods: Treatment-naïve patient data were collected between January 2020 and August 2024 from the European Registry on Helicobacter pylori Management (Hp-EuReg), an international, prospective, multicentre, observational study. Rebamipide-containing regimens were analysed and compared with those without rebamipide. Effectiveness was assessed using a modified intention-to-treat approach. Results: Overall, 4581 patients (mean age 48 ± 15 years, 64% women) from 15 Russian cities were included. From those, 820 patients received eradication therapy with rebamipide and 3761 without rebamipide. Overall effectiveness was significantly higher with rebamipide (731/763, 96%) than without it (2785/3059, 91%) (p = 0.0002). Rebamipide-containing triple therapy consisting of a proton-pump inhibitor (PPI), clarithromycin and amoxicillin was associated with effectiveness above 90%, while rebamipide-containing quadruple therapy consisting of a PPI, clarithromycin, amoxicillin and bismuth yielded a 97% eradication rate, compared with 79% and 95%, respectively, without rebamipide (p < 0.001). Adverse events were significantly more frequent in patients receiving rebamipide-containing regimens (46% vs. 29%, p < 0.0001), though none were serious or caused discontinuation. Compliance was similar in both groups (99% vs. 98.5%; p > 0.05). Conclusions: In this observational registry cohort, first-line empirical triple therapy with amoxicillin–clarithromycin, and quadruple therapy with amoxicillin–clarithromycin–bismuth, both prescribed with rebamipide, were associated with higher eradication rates than regimens without rebamipide.


  • Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Drug-Induced Liver Injury

    by V. T. Ivashkin, О. M. Drapkina, K. L. Raikhelson, S. V. Okovityi, M. V. Maevskaya, V. R. Grechishnikova, M. S. Zharkova, O. V. Khlynova, O. А. Gladkov, T. A. Deeva, et al.

    Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with drug-induced liver injury, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of drug-induced liver injury, peculiarities of its clinical course. Also, the recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for drug-induced liver injury disease and its clinical phenotypes assessment; approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician’s actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with drug- induced liver injury contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.


  • Open Access

    Clinical Recommendations of the Russian Gastroenterological Association for the Diagnosis and Treatment of Autoimmune Gastritis

    by V. T. Ivashkin, I. V. Maev, T. L. Lapina, A. S. Trukhmanov, D. E. Rumyantseva, O. A. Storonova, A. V. Paraskevova, A. S. Tertychnyy, A. P. Kiryukhin, P. V. Pavlov, et al.

    Aim: to present clinical guidelines describing the clinical, laboratory, endoscopic and histological characteristics of autoimmune gastritis (AIG) and to provide information support for decision-making on diagnosis, prognosis assessment and choice of management tactics for patients with AIG. Key points. AIG is an organ-specific autoimmune disease characterized by the presence of antibodies to parietal cells and/or intrinsic factor, in which inflammation and atrophy are limited to the gastric mucosa, functionally manifesting as hypo- and achlorhydria. There is evidence of an increase in the incidence of AIG worldwide. AIG is often associated with autoimmune thyroiditis (up to 40 % of cases), type 1 diabetes mellitus, and autoimmune polyglandular syndrome. Data on laboratory diagnostic methods, esophagogastroduodenoscopy, and histological examination of biopsies are presented, with an analysis of the endoscopic and histological picture typical of AIG. When AIG is combined with H. pylori infection, eradication therapy is recommended. In addition to symptomatic treatment and treatment of anemia, long-term rebamipide therapy is recommended to potentiate the protective properties of the gastric mucosa. Endoscopic monitoring of patients with AIG is recommended at intervals of once every 3 years.


  • Open Access

    Potential of Pharmacological Correction of Gastrointestinal Motility Disorders

    by V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, T. L. Lapina, A. I. Dolgushina, O. Yu. Zolnikova, M. F. Osipenko, D. E. Rumyantseva, V. I. Simanenkov, O. A. Storonova, et al.

    Aim: to present key data on the role of gastrointestinal motility dysfunction in the pathogenesis of functional and organic diseases and the importance of acotiamide in the correction of these disorders and to introduce a resolution of the expert council of the Russian Gastroenterological Association and the Russian Society of Neurogastroenterology and Motility.Key points. Gastrointestinal motility dysfunction represents a key pathogenetic factor that determines the development and clinical course of a broad range of diseases. Functional dyspepsia and gastroesophageal reflux disease are highly prevalent conditions, and motility impairments, such as impaired gastric accommodation and delayed gastric emptying, account for their frequent co-occurrence in the same patient. For the pharmacotherapy of these diseases, drug products with a prokinetic effect are of substantial importance. Acotiamide has a proven prokinetic effect, improves gastric accommodation and emptying, and reduces the severity of symptoms of postprandial distress syndrome and overlapping manifestations of gastroesophageal reflux disease. In a multicenter Russian study, a response to acotiamide therapy was noted in 74.1 % of patients with postprandial distress syndrome versus 51.9 % in the placebo group (p < 0.001). Dysmotility and its association with gastrointestinal symptoms in H. pylori-associated dyspepsia, reflux gastritis, and autoimmune gastritis, as well as therapeutic measures to correct these disorders and alleviate symptoms, require further research.Conclusion. Further research into motility disorders of the gastrointestinal tract will help to elucidate the pathogenesis of a number of functional and organic gastroenterological diseases. The body of evidence from international and local studies confirms the clinical efficacy and safety of acotiamide. Its inclusion in national clinical guidelines justifies the use of the drug product in patients with functional dyspepsia and gastric motility disorders, including cases in combination with gastroesophageal reflux disease.

  • Open Access

    Hepatotropic therapy for drug-induced liver injury (expert meeting)

    by S. V. Okovityi, K. L. Raikhelson, V. А. Akhmedov, L. G. Vologzanina, O. A. Gladkov, V. R. Grechishnikova, T. А. Deeva, A. I. Dolgushina, M. S. Zharkova, I. V. Kozlova, et al.

    A joint council of experts in the field of hepatology reviewed the results of experimental and clinical studies evaluating the efficacy of hepatotropic drugs (ademetionine, ursodeoxycholic acid, ornithine, bicyclol, morpholinium tiazotate, phospholipids, a fixed combination of inosine + meglumine + methionine + nicotinamide + succinic acid), glucocorticoids, extracorporeal detoxification methods in drug-induced liver injury (DILI); inclusion of these medications and treatment methods in clinical guidelines in various countries was analyzed. Indications for the use of hepatotropic drugs were formulated depending on the pattern of DILI (hepatocellular, cholestatic, mixed), as well as in some DILI phenotypes.


  • Open Access

    The Role of Morphological Examination in The Diagnosis of Chronic Autoimmune Gastritis: A Literature Review

    by G. A. Moroz, R. A. Trufanenko, L. M. Grinberg, R. B. Berdnikov, I. G. Danilova, N. D. Sorokina, L. Z. Abduragimova, I. B. Khlynov

    Introduction. In developed countries, there is a trend towards a decrease in the prevalence of H. Pylori associated gastritis, which leads to an increase in the relative frequency of chronic autoimmune gastritis in the structure of gastric lesions in biopsy material. The observed trends, as well as the presumed underdiagnosis of autoimmune gastritis in the Russian Federation make it relevant to discuss the principles of diagnostics of this disease.Objective. Provide current data on the criteria for morphological diagnosis of chronic autoimmune gastritis.Materials and methods. Data on the problem were searched in the databases of scientific publications PubMed, Web of Science, Scopus, eLibrary.ru. The depth of the scientific search was 175 years (1849–2024).Results and discussion. The diagnosis of autoimmune gastritis is reduced to endoscopic examination with biopsy sampling according to the OLGA/Modified Sydney System diagnostic protocol (antral, incisura anglularis and body of the stomach). At the same time serological methods (detection of specific antibodies) do not always allow to confirm or refute the diagnosis, due to the existence of seronegative variant of the disease, which determines the primary role of morphological examination. The publication discusses the differential diagnosis of different stages of autoimmune gastritis with other types of chronic gastritis.Conclusion. Chronic autoimmune gastritis is a diagnosis that involves a gastroenterologist, endoscopist, and pathologist. The leading role of morphological methods in the diagnosis of chronic autoimmune gastritis is determined and substantiated.


  • Open Access

    Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research)

    by V. T. Ivashkin, A. S. Trukhmanov, I. V. Maev, O. M. Drapkina, M. A. Livzan, A. I. Martynov, T. L. Lapina, A. V. Paraskevova, D. N. Andreev, O. P. Alexeeva, et al.

    Aim. These recommendations are developed for practitioners in order to familiarize them with modern diagnostic methods, management features and pharmacotherapy of patients with gastroesophageal reflux disease (GERD).General provisions. GERD is the most common reason for patients to visit clinics. There are esophageal and extraesophageal manifestations of GERD. Patients' complaints of heartburn and regurgitation remain the most sensitive and specific clinical manifestations of GERD. The diagnosis of GERD is established on the basis of anamnestic data, instrumental examination (detection of reflux esophagitis during upper gastrointestinal endoscopy, detection of pathological gastroesophageal reflux with 24-hour pH-metry or/and 24-hour pH-impedance monitoring). Patients with suspected GERD and the absence of erosive and ulcerative changes in the mucous membrane of the esophagus or the presence of erosive esophagitis of Grade A according to Los Angeles Classification of Gastroesophageal Reflux Disease are recommended to conduct 24-hour pH-metry on PPI off to exclude or confirm the diagnosis of GERD. Patients with extraesophageal manifestations of GERD without classic symptoms (heartburn, regurgitation) are recommended to undergo 24-hour pH-impedance monitoring with discontinuation of proton pump inhibitor therapy. When deciding on surgical treatment, all patients need to perform high-resolution esophageal manometry and 24-hour pH-impedance monitoring. Complications of GERD include bleeding, strictures, Barrett’s esophagus and esophageal adenocarcinoma. The main groups of medications used in the treatment of GERD are proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), alginates, antacids, and prokinetics. PPIs are the drugs of choice in the treatment of both symptoms of gastroesophageal reflux disease and existing erosive esophagitis. Combination therapy Rebamipide with PPIs increases the effectiveness of relief of GERD symptoms, as well as reduces the frequency of relapses.Conclusion. These clinical recommendations will improve the quality of medical care for patients with GERD.


  • Open Access

    Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg)

    by Llum Olmedo, Xavier Calvet, Emili Gené, Dmitry S Bordin, Irina Voynovan, M. Castro-Fernandez, Manuel Pabón-Carrasco, Alma Keco-Huerga, Ángeles Perez-Aisa, Alfredo J Lucendo, et al.

    Background: Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Objective: To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg). Design: Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success. Results: Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT—containing bismuth, metronidazole and tetracycline—plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness. Conclusion: The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness. Trial registration number: NCT02328131 .


  • Open Access

    Methodological Guidelines of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterology Association (RGA) on the Use of Probiotics, Prebiotics, Synbiotics, Metabiotics and Functional Foods Enriched with Them for the Treatment and Prevention of Gastrointestinal Diseases in Adults and Children

    by V. T. Ivashkin, A. V. Gorelov, D. I. Abdulganieva, O. P. Alekseeva, S. A. Alekseenko, A. Yu. Baranovsky, I. N. Zakharova, O. Yu. Zolnikova, K. V. Ivashkin, N. Yu. Ivashkina, et al.

       Aim: to optimize outcomes of the treatment and prevention of gastrointestinal diseases in adults and children.   Key points. The Methodological Guidelines contain sections on the terminology, classification, mechanisms of action, requirements for sale in the Russian Federation, requirements for proving the efficacy and safety of probiotics, prebiotics, synbiotics and metabiotics, as well as functional foods enriched with them. An overview of relevant data allowing to include these drugs and products in the treatment an d prevention of gastrointestinal diseases in adults and children is presented.   Conclusion. The clinical efficacy of probiotics, prebiotics, synbiotics and metabiotics depends on the specificity and quantity of their components, the dosage form, the regimen and duration of treatment. Products and functional foods with proven efficacy and safety are recommended for the treatment and prevention of gastrointestinal diseases in adults and children.